New trial
Phase III RT Trial: VLDRT as ionizing radiation for DNA damage in indolent lymphomas
- Trial ID
- NCT07029217 on ClinicalTrials.gov
- Cancer type
- Other Solid Tumors
- Stage of research
- Registrational
- Location
- 7 Locations
- Published in
- New in Oncology - July 3, 2025
Memorial Sloan Kettering Cancer Center is investigating whether very low dose radiotherapy (4 Gy in 1-2 fractions) is as effective as standard treatment (24 Gy in 12 fractions) for untreated indolent B-cell lymphomas including follicular, marginal zone, and MALT lymphomas. This randomized Phase III study evaluates tumor control and side effect profiles using PET-guided response assessment.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings